Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09GFF
|
|||
| Drug Name |
PMID28394193-Compound-27
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
EPIZYME, INC
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C31H38N6O3
|
|||
| Canonical SMILES |
CCC(C)N1C=C(C2=C(C=C(C=C21)C3=CN=C(C=C3)N4CCNCC4)C(=O)NCC5=C(NC(=CC5=O)C)OC)C
|
|||
| InChI |
1S/C31H38N6O3/c1-6-21(4)37-18-19(2)29-24(30(39)34-17-25-27(38)13-20(3)35-31(25)40-5)14-23(15-26(29)37)22-7-8-28(33-16-22)36-11-9-32-10-12-36/h7-8,13-16,18,21,32H,6,9-12,17H2,1-5H3,(H,34,39)(H,35,38)
|
|||
| InChIKey |
RKSMELDENOCZPF-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Enhancer of zeste homolog 2 (EZH2) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Enhancer of zeste homolog 2 (EZH2) | Target's Patent Info | [1] | |
| KEGG Pathway | MicroRNAs in cancer | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Reactome | PRC2 methylates histones and DNA | |||
| Oxidative Stress Induced Senescence | ||||
| PKMTs methylate histone lysines | ||||
| WikiPathways | Interactome of polycomb repressive complex 2 (PRC2) | |||
| Endoderm Differentiation | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| Histone Modifications | ||||
| Cell Differentiation - meta | ||||
| miRs in Muscle Cell Differentiation | ||||
| miR-targeted genes in muscle cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| miR-targeted genes in epithelium - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.